Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-25T17:46:34.321Z Has data issue: false hasContentIssue false

1.10 - Approach to Psychosis in Children and Adolescents

from Part I - Treatment Strategies

Published online by Cambridge University Press:  19 October 2021

Edited by
Michael Cummings  and
Stephen Stahl
Michael Cummings
Affiliation:
University of California, Los Angeles
Stephen Stahl
Affiliation:
University of California, San Diego
Get access

Summary

Psychotic symptoms in children and adolescents are common especially in the context of anxiety and mood disorders. The prevalence is higher in younger children than in adolescents [1]. Assessing, diagnosing and treating young people presenting with psychotic symptoms is challenging. Children have psychotic experiences that may or may not indicate a psychotic spectrum disorder or other psychopathology. In fact, there is evidence that 40–60% of youth with bipolar illness and 15–35% with depression have psychotic symptoms [2]. One must establish a systematic approach when trying to determine the underlying cause of psychosis in children and adolescents. Moreover, it is vital to understand the presentations of schizophrenia that occur in children and adolescents, the psychiatric and medical conditions that have psychotic features, the drugs and medications that can induce a psychotic state, the recommended parameters when assessing and diagnosing youth with psychotic disorders, the recommended parameters when using antipsychotic medications in youth, the effectiveness of different antipsychotics when treating this population, the medications that are currently approved by the U.S. Food and Drug Administration (FDA) for use in children and adolescents and the psychosocial interventions that may ameliorate psychotic symptoms. While no fail-safe approach exists to correctly identify children and adolescents with psychotic disorders, utilizing a systematic structure can increase accuracy, and therefore support development of an appropriate and comprehensive plan of care that will benefit the youth. An African proverb says that it takes a village to raise a child. The same applies when assessing, diagnosing and treating youth with psychosis. It takes collaboration with different disciplines, systems, organizations and working closely with guardians and family members.

Type
Chapter
Information
Management of Complex Treatment-resistant Psychotic Disorders , pp. 60 - 79
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kelleher, I., Connor, D., Clarke, M. C., et al. (2012). Prevalence of psychotic symptoms in childhood and adolescence: a systematic review and meta-analysis of population-based studies. Psychol Med, 42, 1857–1863.CrossRefGoogle ScholarPubMed
Maloney, A. E., Yakutis, L. J., Frazier, J. A. (2012). Empirical evidence for psychopharmacologic treatment in early-onset psychosis and schizophrenia. Child Adolesc Psychiatr Clin, 21, 885–909.CrossRefGoogle ScholarPubMed
McClellan, J., Stock, S. (2013). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry, 52, 976–990.CrossRefGoogle ScholarPubMed
Sikich, L. (2013). Diagnosis and evaluation of hallucinations and other psychotic symptoms in children and adolescents. Child Adolesc Psychiatr Clin, 22, 655–673.CrossRefGoogle ScholarPubMed
McClellan, J. (2018). Psychosis in children and adolescents. J Am Acad Child Adolesc Psychiatry, 57, 308–312.Google Scholar
Reichenberg, A., Caspi, A., Harrington, H., et al. (2010). Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am J Psychiatry, 167, 160–169.CrossRefGoogle ScholarPubMed
Ross, R. G. (2008). New findings on antipsychotic use in children and adolescents with schizophrenia spectrum disorders. Am J Psychiatry, 165(11), 1369–1372.CrossRefGoogle ScholarPubMed
Rapoport, J. L., Gogtay, N. (2011). Childhood onset schizophrenia: support for a progressive neurodevelopmental disorder. Int J Dev Neurosci, 29, 251–258.CrossRefGoogle ScholarPubMed
Penttilä, J., Paillére-Martinot, M-L., Martinot, J-L., et al. (2008). Global and temporal cortical folding in patients with early-onset schizophrenia. J Am Acad Child Adolesc Psychiatry, 47, 1125–1132.CrossRefGoogle ScholarPubMed
Cornblatt, B. A., Lencz, T., Smith, C. W., et al. (2007). Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry, 64(4), 546–557.CrossRefGoogle Scholar
Amminger, G. P., Schäfer, M. R., Papageorgiou, K., et al. (2010). Long-chain ω-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry, 67, 146–154.CrossRefGoogle ScholarPubMed
McGorry, P. D., Nelson, B., Markulev, C., et al. (2017). Effect of ω-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. JAMA Psychiatry, 74, 19–27.CrossRefGoogle ScholarPubMed
Cannon, T. D., Cadenhead, K., Cornblatt, B., et al. (2008). Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry, 65, 28–37.CrossRefGoogle ScholarPubMed
Ienciu, M., Romos¸an, F., Bredicean, C., et al. (2010). First episode psychosis and treatment delay – causes and consequences. Psychiatria Danubina, 22, 540–543.Google Scholar
Rubio, J. M., Sanjuán, J., Flórez-Salamanca, L., et al. (2012). Examining the course of hallucinatory experiences in children and adolescents: a systematic review. Schizophr Res, 138, 248–254.CrossRefGoogle ScholarPubMed
Norman, R. M., Mallal, A. K., Manchanda, R., et al. (2007). Does treatment delay predict occupational functioning in first-episode psychosis? Schizophr Res, 91, 259–262.CrossRefGoogle ScholarPubMed
Poulton, R., Caspi, A., Moffitt, T. E., et al. (2000). Children’s self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch Gen Psychiatry, 57, 1053–1058.CrossRefGoogle ScholarPubMed
Robins, L. N., Helzer, J. E., Croughan, J., et al. (1981). National Institute of Mental Health diagnostic interview schedule: its history, characteristics, and validity. Arch Gen Psychiatry, 38, 381–389.CrossRefGoogle ScholarPubMed
Barrera, M., Garrison-Jones, C. V. (1988). Properties of the Beck Depression Inventory as a screening instrument for adolescent depression. J Abnorm Child Psychol, 16, 263–273.CrossRefGoogle ScholarPubMed
Jellinek, M. S., Murphy, J. M., Robinson, J., et al. (1988). Pediatric Symptom Checklist: screening school-age children for psychosocial dysfunction. J Pediatrics, 112, 201–209.CrossRefGoogle ScholarPubMed
Werry, J. S., McClellan, J. M., Chard, L. (1991). Childhood and adolescent schizophrenic, bipolar, and schizoaffective disorders: a clinical and outcome study. J Am Acad Child Adolesc Psychiatry, 30, 457–465.CrossRefGoogle ScholarPubMed
Carlson, G. A., Fennig, S., Bromet, E. J. (1994). The confusion between bipolar disorder and schizophrenia in youth: where does it stand in the 1990s? J Am Acad Child Adolesc Psychiatry, 33, 453–460.CrossRefGoogle ScholarPubMed
Kaufman, J., Birmaher, B., Brent, D., et al. (1997). Schedule for affective disorders and schizophrenia for school-age children – present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry, 36, 980–988.CrossRefGoogle ScholarPubMed
Conners, C. K., Sitarenios, G., Parker, J. D., et al. (1998). The revised Conners’ Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol, 26, 257–268.CrossRefGoogle ScholarPubMed
Angold, A., Costello, E. J. (2000). The child and adolescent psychiatric assessment (CAPA). J Am Acad Child Adolesc Psychiatry, 39, 39–48.CrossRefGoogle ScholarPubMed
Muris, P., Schmidt, H., Merckelbach, H. (2000). Correlations among two self-report questionnaires for measuring DSM-defined anxiety disorder symptoms in children: The Screen for Child Anxiety Related Emotional Disorders and the Spence Children’s Anxiety Scale. Pers Individ Differ, 28, 333–346.CrossRefGoogle Scholar
Geller, B., Zimerman, B., Williams, M., et al. (2001). Reliability of the Washington University in St. Louis Kiddie Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS) mania and rapid cycling sections. J Am Acad Child Adolesc Psychiatry, 40, 450–455.CrossRefGoogle Scholar
Lachar, D., Randle, S. L., Harper, R. A., et al. (2001). The brief psychiatric rating scale for children (BPRS-C): validity and reliability of an anchored version. J Am Acad Child Adolesc Psychiatry, 40, 333–340.CrossRefGoogle ScholarPubMed
Gracious, B. L., Youngstrom, E. A., Findling, R. L., et al. (2002). Discriminative validity of a parent version of the Young Mania Rating Scale. J Am Acad Child Adolesc Psychiatry, 41, 1350–1359.CrossRefGoogle ScholarPubMed
Group, R. U. o. P. P. A. S. (2002). The pediatric anxiety rating scale (PARS): development and psychometric properties. J Am Acad Child Adolesc Psychiatry, 41, 1061–1069.CrossRefGoogle Scholar
Knight, J. R., Sherritt, L., Shrier, L. A., et al. (2002). Validity of the CRAFFT substance abuse screening test among adolescent clinic patients. Arch Pediatr Adolesc Med, 156, 607–614.CrossRefGoogle ScholarPubMed
Kroenke, K., Spitzer, R. L. (2002). The PHQ-9: a new depression diagnostic and severity measure. Psychiatr Ann, 32, 509–515.CrossRefGoogle Scholar
Mohamadesmaiel, E., Alipour, A. (2002). A preliminary study on the reliability, validity and cut off points of the disorders of Children Symptom Inventory-4 (CSI-4). J Except Child, 2, 239–254.Google Scholar
Brooks, S. J., Krulewicz, S. P., Kutcher, S. (2003). The Kutcher Adolescent Depression Scale: assessment of its evaluative properties over the course of an 8-week pediatric pharmacotherapy trial. J Child Adolesc Psychopharmacol, 13, 337–349.CrossRefGoogle ScholarPubMed
Pavuluri, M. N., Herbener, E. S., Sweeney, J. A. (2004). Psychotic symptoms in pediatric bipolar disorder. J Affect Disord, 80, 19–28.CrossRefGoogle ScholarPubMed
Timbremont, B., Braet, C., Dreessen, L. (2004). Assessing depression in youth: relation between the Children’s Depression Inventory and a structured interview. J Clin Child Adolesc Psychol, 33, 149–157.CrossRefGoogle ScholarPubMed
III Hale, W. W., Raaijmakers, Q., Muris, P., et al. (2005). Psychometric properties of the Screen for Child Anxiety Related Emotional Disorders (SCARED) in the general adolescent population. J Am Acad Child Adolesc Psychiatry, 44, 283–290.CrossRefGoogle ScholarPubMed
Perrin, S., Meiser-Stedman, R., Smith, P. (2005). The Children’s Revised Impact of Event Scale (CRIES): validity as a screening instrument for PTSD. Behav Cog Psychother, 33, 487–498.CrossRefGoogle Scholar
Pappas, D. (2006). ADHD Rating Scale-IV: checklists, norms, and clinical interpretation. J Psychoed Assess, 24, 172–178.CrossRefGoogle Scholar
Wagner, K. D., Hirschfeld, R., Emslie, G. J., et al. (2006). Validation of the Mood Disorder Questionnaire for bipolar disorders in adolescents. J Clin Psychiatry, 67(5), 827–830.CrossRefGoogle ScholarPubMed
Chandler, S., Charman, T., Baird, G., et al. (2007). Validation of the social communication questionnaire in a population cohort of children with autism spectrum disorders. J Am Acad Child Adolesc Psychiatry, 46, 1324–1332.CrossRefGoogle Scholar
Charman, T., Baird, G., Simonoff, E., et al. (2007). Efficacy of three screening instruments in the identification of autistic-spectrum disorders. Br J Psychiatry, 191, 554–559.CrossRefGoogle ScholarPubMed
Polderman, T. J., Derks, E. M., Hudziak, J. J., et al. (2007). Across the continuum of attention skills: a twin study of the SWAN ADHD rating scale. J Child Psychol Psychiatry, 48, 1080–1087.CrossRefGoogle ScholarPubMed
Gallant, J., Storch, E. A., Merlo, L. J., et al. (2008). Convergent and discriminant validity of the Children’s Yale-Brown Obsessive Compulsive Scale-symptom checklist. J Anxiety Disord, 22, 1369–1376.Google Scholar
Kaminer, Y. (2008). The teen addiction severity index around the globe: the tower of Babel revisited. Subst Abuse, 29, 89–94.Google Scholar
Lanktree, C. B., Gilbert, A. M., Briere, J., et al. (2008). Multi-informant assessment of maltreated children: convergent and discriminant validity of the TSCC and TSCYC. Child Abuse Negl, 32, 621–625.CrossRefGoogle ScholarPubMed
Winters, K. C., Kaminer, Y. (2008). Screening and assessing adolescent substance use disorders in clinical populations. J Am Acad Child Adolesc Psychiatry, 47, 740.Google Scholar
Mayes, S. D., Calhoun, S. L., Murray, M. J., et al. (2009). Comparison of scores on the Checklist for Autism Spectrum Disorder, Childhood Autism Rating Scale, and Gilliam Asperger’s Disorder Scale for children with low functioning autism, high functioning autism, Asperger’s disorder, ADHD, and typical development. J Aut Dev Disord, 39, 1682–1693.CrossRefGoogle ScholarPubMed
Nakamura, B. J., Ebesutani, C., Bernstein, A., et al. (2009). A psychometric analysis of the child behavior checklist DSM-oriented scales. J Psychopathol Behav Assess, 31, 178–189.CrossRefGoogle Scholar
Posserud, M-B., Lundervold, A. J., Gillberg, C. (2009). Validation of the autism spectrum screening questionnaire in a total population sample. J Aut Dev Disord, 39, 126–134.CrossRefGoogle Scholar
Chlebowski, C., Green, J. A., Barton, M. L., et al. (2010). Using the childhood autism rating scale to diagnose autism spectrum disorders. J Aut Dev Disord, 40, 787–799.CrossRefGoogle ScholarPubMed
Reynolds, C. R. (2010). Behavior assessment system for children. The Corsini Encyclopedia of Psychology, 1–2.CrossRefGoogle Scholar
Becker, S. P., Langberg, J. M., Vaughn, A. J., et al. (2012). Clinical utility of the Vanderbilt ADHD diagnostic parent rating scale comorbidity screening scales. J Dev Behav Pediatr, 33, 221.Google Scholar
Fux, L., Walger, P., Schimmelmann, B. G., et al. (2013). The schizophrenia proneness instrument, child and youth version (SPI-CY): practicability and discriminative validity. Schizophr Res, 146, 69–78.Google Scholar
Martinez, W., Polo, A. J., Zelic, K. J. (2014). Symptom variation on the Trauma Symptom Checklist for Children: a within-scale meta-analytic review. J Traumatic Stress, 27, 655–663.CrossRefGoogle ScholarPubMed
Stucky, B. D., Edelen, M. O., Ramchand, R. (2014). A psychometric assessment of the GAIN General Individual Severity Scale (GAIN-GISS) and Short Screeners (GAIN-SS) among adolescents in outpatient treatment programs. J Subst Abuse Treat, 46, 165–173.CrossRefGoogle ScholarPubMed
Sparrow, S., Cicchetti, D. V., Saulnier, C. A. (2016). Vineland adaptive behavior scales (Vineland-3). Antonio: Psychological Corporation.Google Scholar
Pagsberg, A. K., Tarp, S., Glintborg, D., et al. (2017). Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis. J Am Acad Child Adolesc Psychiatry, 56, 191–202.CrossRefGoogle ScholarPubMed
Craddock, K. E., Zhou, X., Liu, S., et al. (2018). Symptom dimensions and subgroups in childhood-onset schizophrenia. Schizophr Res, 197, 71–77.CrossRefGoogle ScholarPubMed
Doric, A., Stevanovic, D., Stupar, D., et al. (2019). UCLA PTSD reaction index for DSM-5 (PTSD-RI-5): a psychometric study of adolescents sampled from communities in eleven countries. Eur J Psychotraumatology, 10, 1605282.CrossRefGoogle ScholarPubMed
Child Mind Institute. (2017). Children’s Mental Health Report. Available from: https://childmind.org/report/2017-childrens-mental-health-report (last accessed November 3, 2020).Google Scholar
Galynker, I., Ieronimo, C., Perez-Acquino, A., et al. (1996). Panic attacks with psychotic features. J Clin Psychiatry, 57, 402–406.Google ScholarPubMed
Schäfer, I., Fisher, H. L. (2011). Childhood trauma and psychosis – what is the evidence? Dialogues Clin Neurosci, 13, 360.CrossRefGoogle ScholarPubMed
Rodowski, M. F., Cagande, C. C., Riddle, M. A. (2008). Childhood obsessive-compulsive disorder presenting as schizophrenia spectrum disorders. J Child Adolesc Psychopharmacol, 18, 395–401.CrossRefGoogle ScholarPubMed
American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders. Arlington: American Psychiatric Association, p. 81.Google Scholar
Mullin, A., Gokhale, A., Moreno-De-Luca, A., et al. (2013). Neurodevelopmental disorders: mechanisms and boundary definitions from genomes, interactomes and proteomes. Transl Psychiatry, 3, e329–e329.CrossRefGoogle ScholarPubMed
Landa, R. J., Gross, A. L., Stuart, E. A., et al. (2013). Developmental trajectories in children with and without autism spectrum disorders: the first 3 years. Child Dev, 84, 429–442.CrossRefGoogle ScholarPubMed
McNamara, D. (2012). Genetic microarrays grow for neurodevelopmental diagnosis. Available from: www.mdedge.com/clinicalneurologynews/article/52657/neurology/genetic-microarrays-grow-neurodevelopmental-diagnosis (last accessed November 3, 2020).Google Scholar
Fluyau, D., Mitra, P., Lorthe, K. (2019). Antipsychotics for amphetamine psychosis. A systematic review. Front Psychiatry, 10, 740.CrossRefGoogle ScholarPubMed
Cheng, W-J., Chen, C-H., Chen, C-K., et al. (2018). Similar psychotic and cognitive profile between ketamine dependence with persistent psychosis and schizophrenia. Schizophr Res, 199, 313–318.CrossRefGoogle ScholarPubMed
American Addiction Centers. (2019). Dextromethorphan abuse. Available from: www.drugabuse.com/dextromethorphan (last accessed November 3, 2020).Google Scholar
Abraham, H. D. (1983). Visual phenomenology of the LSD flashback. Arch Gen Psychiatry, 40(8), 884–889.CrossRefGoogle ScholarPubMed
National Institute on Drug Abuse. (2019). Hallucinogens Drug Facts. Available from: www.drugabuse.gov/publications/drugfacts/hallucinogens (last accessed November 3, 2020).Google Scholar
National Institute on Drug Abuse. (2019). Marijuana Drug Facts. Available from: http://www.drugabuse.gov/publications/drugfacts/marijuana (last accessed November 3, 2020).Google Scholar
National Institute on Drug Abuse. (2018). Synthetic Cannabinoids Drug Facts. Avavilable from: http://www.drugabuse.gov/publications/drugfacts/synthetic-cannabinoids-k2spice (last accessed November 3, 2020).Google Scholar
National Institute on Drug Abuse. (2018). Synthetic Cathinones Drug Facts. Available from: http://www.drugabuse.gov/publications/drugfacts/synthetic-cathinones-bath-salts (last accessed November 3, 2020).Google Scholar
Fohrman, D. A., Stein, M. T. (2006). Psychosis: 6 steps rule out medical causes in kids. Curr Psychiatr, 5, 35–47.Google Scholar
Stevens, J. R., Prince, J. B., Prager, L. M., et al. (2014). Psychotic disorders in children and adolescents: a primer on contemporary evaluation and management. Prim Care Companion CNS Disord, 16, PCC.13f01514.Google Scholar
Lowenthal, E. D., Cruz, N., Yin, D. (2010). Neurologic and psychiatric manifestations of pediatric HIV infection. HIV Curriculum for the Health Professional, 194–205.Google Scholar
Ramsey, D., Muskin, P. R. (2013). Vitamin deficiencies and mental health: how are they linked. Curr Psychiatr, 12, 37–43.Google Scholar
Firth, J., Carney, R., Stubbs, B., et al. (2018). Nutritional deficiencies and clinical correlates in first-episode psychosis: a systematic review and meta-analysis. Schizophr Bull, 44, 1275–1292.Google Scholar
American Academy of Child and Adolescent Psychiatry. (2011). Practice parameters for the use of atypical antipsychotics medication in children and adolescents. Available from: https://www.aacap.org/App_Themes/AACAP/docs/practice_parameters/Atypical_Antipsychotic_Medications_Web.pdfGoogle Scholar
Werry, J. S., Weiss, G., Douglas, V., et al. (1966). Studies on the hyperactive child: III. The effect of chlorpromazine upon behavior and learning ability. J Am Acad Child Psychiatry, 5, 292–312.CrossRefGoogle Scholar
Engelhardt, D. M., Polizos, P., Waizer, J., et al. (1973). A double-blind comparison of fluphenazine and haloperidol in outpatient schizophrenic children. J Aut Child Schizophr, 3, 128–137.CrossRefGoogle ScholarPubMed
Pool, D., Bloom, W., Mielke, D., et al. (1976). A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr Therapeut Res, 19(1), 99–104.Google ScholarPubMed
Spencer, E. K., Kafantaris, V., Padron-Gayol, M. V., et al. (1992). Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacol Bull, 28(2), 183–186.Google ScholarPubMed
Kumra, S., Frazier, J. A., Jacobsen, L. K., et al. (1996). Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry, 53, 1090–1097.CrossRefGoogle ScholarPubMed
Woods, S. W., Breier, A., Zipursky, R. B., et al. (2003). Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry, 54, 453–464.Google Scholar
Sikich, L., Hamer, R. M., Bashford, R. A., et al. (2004). A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology, 29, 133–145.CrossRefGoogle ScholarPubMed
McGlashan, T. H., Zipursky, R. B., Perkins, D., et al. (2006). Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry, 163, 790–799.CrossRefGoogle ScholarPubMed
Shaw, P., Sporn, A., Gogtay, N., et al. (2006). Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry, 63, 721–730.CrossRefGoogle ScholarPubMed
Berger, G. E., Proffitt, T-M., McConchie, M., et al. (2008). Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years. J Clin Psychiatry, 69, 1702–1714.CrossRefGoogle ScholarPubMed
Findling, R. L., Robb, A., Nyilas, M., et al. (2008). A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry, 165, 1432–1441.CrossRefGoogle ScholarPubMed
Sikich, L., Frazier, J. A., McClellan, J., et al. (2008). Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry, 165, 1420–1431.Google Scholar
Haas, M., Unis, A. S., Armenteros, J., et al. (2009). A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol, 19, 611–621.CrossRefGoogle ScholarPubMed
Kryzhanovskaya, L., Schulz, S. C., Mcdougle, C., et al. (2009). Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry, 48, 60–70.Google Scholar
Findling, R. L., Johnson, J. L., McClellan, J., et al. (2010). Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry, 49, 583–594.Google ScholarPubMed
Singh, J., Robb, A., Vijapurkar, U., et al. (2011). A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biological Psychiatry, 70, 1179–1187.CrossRefGoogle ScholarPubMed
Findling, R. L., McKenna, K., Earley, W. R., et al. (2012). Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol, 22, 327–342.CrossRefGoogle Scholar
Savitz, A. J., Lane, R., Nuamah, I., et al. (2015). Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study. J Am Acad Child Adolesc Psychiatry, 54, 126–137. e121.Google Scholar
Goldman, R., Loebel, A., Cucchiaro, J., et al. (2017). Efficacy and safety of lurasidone in adolescents with schizophrenia: a 6-week, randomized placebo-controlled study. J Child Adolesc Psychopharmacol, 27, 516–525.CrossRefGoogle ScholarPubMed
Lytle, S., McVoy, M., Sajatovic, M. (2017). Long-acting injectable antipsychotics in children and adolescents. J Child Adolesc Psychopharmacol, 27, 2–9.CrossRefGoogle ScholarPubMed
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353, 1209–1223.CrossRefGoogle ScholarPubMed
Stahl, S. M. (2019). Stahl’s Essential Psychopharmacology: Prescriber’s Guide, Children and Adolescents. New York: Cambridge University Press.Google Scholar
Stevens, J. R., Prince, J. B. (2012). Schooling students with psychotic disorders. Child Adolesc Psychiatr Clin N Am, 21(1), 187–200.CrossRefGoogle ScholarPubMed
Xia, J., Merinder, L. B., Belgamwar, M. R. (2011). Psychoeducation for schizophrenia. Cochrane Database Syst Rev, 2011(6), CD002831.Google ScholarPubMed
Turkington, D., Kingdon, D., Turner, T. (2002). Effectiveness of a brief cognitive–behavioural therapy intervention in the treatment of schizophrenia. Br J Psychiatry, 180, 523–527.CrossRefGoogle ScholarPubMed
McGorry, P. D., Yung, A. R., Phillips, L. J., et al. (2002). Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry, 59, 921–928.CrossRefGoogle Scholar
Wykes, T., Newton, E., Landau, S., et al. (2007). Cognitive remediation therapy (CRT) for young early onset patients with schizophrenia: an exploratory randomized controlled trial. Schizophr Res, 94, 221–230.CrossRefGoogle ScholarPubMed
Lee, R., Redoblado-Hodge, M., Naismith, S., et al. (2013). Cognitive remediation improves memory and psychosocial functioning in first-episode psychiatric out-patients. Psychol Med, 43, 1161–1173.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×